Table 4

Findings from SNOWDROP trial in postmenopausal women.

SNOWDROP TRIAL23

Findings

Naturally postmenopausal women with HSDD (n ​= ​481 Placebo, n ​= ​468 flibanserin 100 ​mg HS) for 24 weeks.

Mean (SE) change from baseline in FSFI score Placebo: 0.4 (0.1) flibanserin100 mg HS: 0.7 (0.1), P ​< ​0.001

Mean (SE) change from baseline in SSEs Placebo: 0.6 (0.1) flibanserin100 mg HS: 1.0 (0.1), P ​= ​0.004

Most common AEs: dizziness (9.9%), somnolence (8.8%), nausea (7.5%); discontinuation due to AEs: 8.1% of flibanserin treated patients